Background: A vaccine has recently been licensed in many countries that protects against
the human papillomavirus types 6, 11, 16, and 18. Types 6 and 11 account for approximately …

Background. Reducing the number of doses in the human papillomavirus (HPV) vaccination
regimen from 3 to 2 could increase coverage rates. In this cohort study, we assessed the risk …

Background In Australia, high uptake of the quadrivalent human papillomavirus (4vHPV)
vaccine has led to reductions in the prevalence of human papillomavirus (HPV) genotypes …

Background. Data on the natural history of human papillomavirus (HPV)–related genital
warts (GWs) in men are sparse. We described the distribution of HPV types in incident GWs …

In a large health insurance database in Germany, incidence of anogenital warts among 15-
to 19-year-old females decreased from 316/100,000 person-years in 2007 to 242 in 2008 …

Background: A National human papilloma virus (HPV) Vaccination Programme for the
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …

Background Reduction in the prevalence of vaccine type HPV infection in young women is
an early indication of the impact of the HPV immunisation programme and a necessary …

Objectives The human papillomavirus (HPV) immunisation programme in England was
introduced in 2008. Monitoring changes in type-specific HPV prevalence allows assessment …

Objectives To estimate the loss of quality of life and cost of treatment associated with genital
warts seen in sexual health clinics. Methods A cross-sectional questionnaire study and case …

Background: Genital warts are caused by human papillomavirus (HPV); over 90% are due to
HPV types 6 and 11. We determined the percentage of persons who reported having been …